Avidity Biosciences, Inc.RNA
Market cap
$9.1B
P/E ratio
| Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Collaboration revenue | 7 | 9 | 9 | 10 | 11 |
| Research and development | 38 | 101 | 150 | 191 | 304 |
| General and administrative | 13 | 26 | 38 | 54 | 86 |
| Total operating expenses | 51 | 127 | 188 | 245 | 390 |
| Loss from operations | -44 | -118 | -179 | -236 | -379 |
| Interest income | 0 | 0 | 5 | 24 | 57 |
| Other expense | - | -0 | -0 | -1 | -0 |
| Total other income | -0 | 0 | 5 | 23 | 57 |
| Net loss | -44 | -118 | -174 | -212 | -322 |
| Earnings Per Share, Basic | - | - | -3.34 | -2.91 | -2.89 |
| Earnings Per Share, Diluted | - | - | -3.34 | -2.91 | -2.89 |
| Net unrealized gains (losses) on marketable securities | - | - | - | 3 | 3 |
| Comprehensive loss | -44 | -118 | -177 | -209 | -320 |